Anaplastic Thyroid Carcinoma: A Therapeutic Dilemma.
10.3349/ymj.2005.46.6.759
- Author:
Hang Seok CHANG
1
;
Kee Hyun NAM
;
Woung Youn CHUNG
;
Cheong Soo PARK
Author Information
1. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Anaplastic thyroid cancer;
treatment modalities;
treatment outcome
- MeSH:
Treatment Outcome;
Thyroid Neoplasms/mortality/surgery/*therapy;
Survival Analysis;
Radiotherapy, Adjuvant;
Neoplasm Metastasis;
Middle Aged;
Male;
Humans;
Female;
Combined Modality Therapy;
Chemotherapy, Adjuvant;
Carcinoma/mortality/surgery/*therapy;
Aged, 80 and over;
Aged;
Adult
- From:Yonsei Medical Journal
2005;46(6):759-764
- CountryRepublic of Korea
- Language:English
-
Abstract:
Anaplastic thyroid carcinoma (ATC) is one of the most malignant human neoplasms and has a grave prognosis. This study gives an update on our experience with this unusual neoplasm, with specific focus on the response to various treatment modalities. Forty-seven patients with histologically proven ATCs were enrolled (19 men, 28 women; mean age, 62.8 years). This number represents 1.5% among a total of 3, 088 thyroid cancers treated between 1977 and 2002. The mean tumor diameter was 8.8 cm, and 22 patients had distant metastasis. Extrathyroidal extension was seen in 26 (89.7%) of the cases that underwent surgery. Treatment modalities adopted could be classified into 5 groups: Group 1, biopsy only; Group 2, biopsy and chemoradiotherapy; Group 3, debulking only; Goup 4, debulking and chemoradiotherapy; Group 5, complete excision and chemoradiotherapy. Survival was calculated from the time of diagnosis, and comparisons of survival were done by log-rank analysis. The mean survival was 4.3 months (range, 1.0-21 months). The mean survival based on treatment modalities were as follows: Group 1 (n = 10), 2.1 months, Group 2 (n = 8) ; 3.6 months; Group 3 (n = 7), 3.0 months; Group 4 (n = 14), 3.5 months, Group 5 (n = 8), 9.4 months. There was no significant difference in survival time between the various types of treatment modalities. Even though a small improvement in survival was observed with complete excision and aggressive multimodality therapy, nearly all ATCs remain unresponsive to ongoing treatment modalities and as such, present a therapeutic dilemma. A more effective treatment regimen should be sought in order to improve survival.
